BRISBANE, Calif., July 28, 2022--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation and top spot, for the third year in a row, as a Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons (ASTS) Summer Winter Symposium, taking place August 4-7, in Miami, Florida.
"CareDx’s industry-leading support of this year’s ASTS Symposium as the exclusive Distinguished Founder’s Circle sponsor demonstrates our enduring commitment and shared mission to driving the next wave of innovation to improve long-term transplantation outcomes," said Reg Seeto, CEO and President of CareDx. "We are excited to host two symposiums featuring a stellar line-up of prominent leaders in transplantation covering the latest advancements in molecular surveillance and the use of our newly introduced XenoSure™ donor-derived cell-free DNA in xenotransplantation research."
CareDx will be hosting two symposiums and presenting two abstracts highlighting the company’s scientific advancements in transplantation.
The Next Frontier: From Observation to Intervention with Molecular Surveillance. Friday, August 5, 7:00-7:45am EST (4:00-4:45am PST). Speakers: Dr. Jeffrey Rogers, CareDx; Dr. Peter Friend, Oxford University; Dr. Christian Larsen, Emory University; Dr. Velma Scantlebury, Texas Christian University.
Molecular Characterization and Prediction of Allograft Outcomes: Where We Are and Where We’re Going. The presentation includes an update on xenotransplantation. Friday, August 5, 11:00am-12:00pm EST (8:00-9:00am PST). Speakers: Dr. Sham Dholakia, CareDx; Dr. Rebecca Craig-Schapiro, Weill Cornell; Dr. Irene Kim, Cedars-Sinai Medical Center; Dr. Robert A. Montgomery, NYU Langone Health; Dr. Velma Scantlebury, Texas Christian University; and Dr. Jason R. Wellen, Washington University.
Posters Featuring CareDx: Poster Session, August 4, 5:30-7:00pm EST (2:30-4:00pm PST).
Abstract Number/ Presenter(s)
Donor-Derived Cell-Free DNA as a Graft Injury Marker Following Kidney Transplantation
P-89/ Ryan Lane and Dr. Liise Kayler
Utility of Donor-derived Cell-Free DNA to Monitor Treatment Response in Pediatric Renal Transplant Recipients with Rejection
P-152/Drs. Justin Steggerda and Irene Kim
"We value CareDx’s leadership and commitment to advancing our collective cause of improving outcomes in transplantation," said Dr. William C. Chapman, ASTS President and Chief of the Section of Transplant Surgery, Chief of Division of General Surgery and the Eugene M. Bricker Professor of Surgery at Washington University School of Medicine. "By being the top sponsor of our ASTS 2022 Summer Winter Symposium, CareDx is uplifting an important event that plays a key role in fostering innovation among world-class transplant leaders."
About CareDx –The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading participation and sponsorship of the 2022 American Society of Transplant Surgeons (ASTS) Summer Winter Symposium (the "ASTS Symposium"). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of CareDx’s leading participation and sponsorship of the ASTS Symposium; risks that CareDx fails to host its symposiums or present its abstracts and posters at the time and place shown in this press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the first quarter of 2022 ended on March 31, 2022 filed by CareDx with the SEC on May 5, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005529/en/